The therapeutic community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant efficacy in clinical retatrutide energy trials for treating obesity. Unlike some available weight loss solutions, retatrutide appears to provide a greater substantial loss in body size and benefit metabolic ma